Georgia Healthcare Group PLC Annual Report 2018 Governance Clinical Quality and Safety Committee Report Mike Anderson Chairman of the Clinical Quality and Safety Committee Chairman’s Overview In September 2018, Fabian Blank joined the Board and was I am delighted to present my report for 2018. appointed to the Committee and replaced Ingeborg Oie following her appointment to the Audit Committee. I would like to thank Ingeborg I see the role of the Committee as being centred on ensuring that for her valuable contribution to the Committee. In December 2018 as the Group grows, the care provided to those in our facilities is the Committee reviewed its terms of reference to ensuring that of a consistently high level and that the Group continues to deliver the Committee is best placed to continue to drive continued on improvements in clinical quality and safety in each of its facilities. improvements in clinical quality and safety. We aim to ensure these high standards are delivered consistently irrespective of where in the country our patients are receiving care. I invite you to read more about these and the other main activities of the Committee in the report below. I am pleased to report that we have made significant progress this year, particularly in terms of the quality of clinical data available to us as a Committee. This provides an excellent benchmark for us to understand where we are working well and the reasons why we workMike Anderson well, and to gain insight into further improvements that are required. Chairman of the Clinical Quality and Safety Committee 2 April 2019 Although we are pleased to see the progress in clinical care and quality this year, we are not complacent. We see, for example, that many of our facilities are delivering outstanding levels of care Key Responsibilities to patients but we need to continue to build on this. There remains The Clinical Quality and Safety Committee supports the Board in more for us to do to deliver the consistency in standards of care overseeing the Group’s non-financial risks and their associated risk that we challenge ourselves as a Group to provide. management framework including the related governance, internal control systems and assurance. The Committee’s work aims to The opening of the Mega Laboratory in December 2018 is an promote a culture where quality and safe patient care are at the important step in improving our clinical and pathology testing and centre of management’s actions. represents a new benchmark in both Georgia and the wider Caucasus region. The launch is in line with the Group’s wider strategy to invest The key responsibilities of the Clinical Quality and Safety Committee in and develop new medical services to keep filling existing service are to: gaps in the country, supporting the market’s continuing development • promote a culture of high-quality and safe patient care and and our services export strategy. experience, which recognises the importance of health and safety and risk management; I reported in last year’s Annual Report that, alongside the Group’s • review the Group’s clinical performance, including against KPIs, Audit Committee, the Committee would continue to focus in 2018 on providing recommendations and information to the Board to enable ensuring that the Group’s clinical risk management framework, which them to discharge its responsibilities in relation to the matters is vital for our business and the safety and wellbeing of our patients, reserved to it; continued to be embedded across the Group. The Committee has • scrutinise the adequacy, effectiveness and quality of the Group’s continued to receive reports at each meeting on the progress made clinical services, governance, audit and risk management by management in rolling out the framework and we are very pleased processes and policies (including in relation to infection control) to to see the levels of engagement with the framework shown by ensure the delivery of safe high-quality clinical services to patients; our clinical managers across all our facilities; we have made visible • monitor unexpected deaths occurring in hospital sites, ensuring progress in this area and a focus for the Committee in 2019 will be that root causes, action plans are adequate, and reporting on such to ensure that we continue to build on this progress. monitoring activities to the Board; • review evidence of compliance with statutory notification I would like to take this opportunity to thank both management and requirements, as well as responses to statutory notices issued clinicians for the service they continue to provide to the Group and to by competent authorities, and report these to the Board; our patients. As a Committee, we have made a point to visit a number • review evidence of compliance with regulation and best practice of the Group’s facilities across Georgia throughout 2018 and we continue and the Company’s policies and procedures in respect of clinical to be deeply impressed by the dedication and tirelessness of all staff. care and quality, and reporting this to the Board; 82